The company is currently working on multiple programs, including FT500, FT516, FT-ONO2, and FATE-NK100 for the treatment of advanced solid tumors. Fate Therapeutics has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications. Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Our dashboard, What Factors Drove 1771% Change in Fate Therapeutics Stock between 2017 end and now?, has the underlying numbers. Try the Trefis machine learning engine above to see for yourself how Fate Therapeutics stock is likely to behave after any specific gain or loss over a period. Case 1: Fate Therapeutics stock drops by -5% or more in a week, Case 2: Fate Therapeutics stock rises by 5% or more in a week. Under terms of the agreement, Fate will receive $50 million in upfront cash, as well as a $50 million equity investment by Janssen. Assignee: FATE THERAPEUTICS, INC. 22 Wall Street research analysts have issued twelve-month price objectives for Fate Therapeutics' stock. View analysts price targets for FATE or view top-rated stocks among Wall Street analysts. The outperformance of FATE can be attributed to positive findings from early clinical trials of FT500 and FT516 treatments. Fate Therapeutics is funded by 8 investors. Tesla Investors Arent Impressed With Elon Musk. Topics covered: Drug commercialization, pharma salesforces, generic and biosimilar competition, drug advertising and much more. Quantbot Technologies LP bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $69,000. I, Fate Therapeutics, Inc. Forecasted to Post Q1 2023 Earnings of ($0.75) Per Share (NASDAQ:FATE), Q1 2023 EPS Estimates for Fate Therapeutics, Inc. (NASDAQ:FATE) Reduced by Analyst, Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call Transcript, Fate Therapeutics Full Year 2022 Earnings: Beats Expectations. So whats the likely trigger and timing for downside? Answer: The average return after a rise is understandably lower than a fall as detailed in the previous question. Receive FATE Stock News and Ratings via Email. The stock has a market capitalization of $599.76 million, a P/E ratio of -2.10 and a beta of 1.53. The rise can largely be attributed to increased investor expectations from Fates pipeline, which focuses on a class of treatment that is based on Natural Killer cells. Case 1: Fate Therapeutics stock drops by -5% or more in a week, Case 2: Fate Therapeutics stock rises by 5% or more in a week. Some Fun Scenarios, FAQs & Making Sense of Fate Therapeutics Stock Movements:uestion 1: Is the average return for Fate Therapeutics stock higher after a drop? Interestingly, though, if a stock has gained over the last few days, you would do better to avoid short-term bets for most stocks - although FATE stock appears to be an exception to this general observation. The data from the trials showed that eight of eleven patients being evaluated for assessment of safety and efficacy of the FT516 treatment achieved an objective response, while six of those patients achieved a complete response. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The partnership will leverage San Diego-based Fate Therapeutics induced pluripotent stem cell (iPSC) product platform and Janssens proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell product candidates that will be developed against up to four tumor-associated antigens for hematologic malignancies and solid tumors. Now that FATE stock has seen a rise of 9% in five trading days, can it continue its upward trajectory, or is a decline imminent? Try the Trefis machine learning engine above to see for yourself how Fate Therapeutics stock is likely to behave after any specific gain or loss over a period. CULVER CITY & EL SEGUNDO, Calif., March 9, 2021 ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock merger.This follows the satisfaction of all customary closing conditions, including approval of the merger by a majority of unaffiliated shareholders of . 17.34% of the stock of Fate Therapeutics is held by insiders. Fate Therapeutics ( FATE) - Get Free Report stock tumbled Friday after the biopharma reported mixed results from a clinical trial of its treatment for B-cell lymphoma. 22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. FATE - Fate Therapeutics, Inc. Stock Price and Quote TIP: Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. Giu 11, 2022 | narcissistic withdrawal. See our analysis on Fate Therapeutics Stock Chances of Rise for more details. The collaboration strengthens our financial and operating position through a focused effort of developing cell-based cancer immunotherapies utilizing Janssens proprietary antigen-binding domains while enabling us to continue to exploit our deep pipeline of wholly-owned product candidates and further develop our off-the-shelf, iPSC-derived cell-based immunotherapies, Wolchko said in a statement. Their FATE share price forecasts range from $7.00 to $90.00. 17.34% of the stock is owned by insiders. Following the completion of the transaction, the chief executive officer now owns 385,639 shares of the companys stock, valued at approximately $2,020,748.36. Analysts like Fate Therapeutics less than other Medical companies. Out of 352 instances in the last eight years that Fate Therapeutics stock saw a five-day rise of 9% or more, 178 of them resulted in FATE stock rising over the subsequent one month period (twenty-one trading days). Question 3: What about the average return after a rise if you wait for a while? However, any positive outcome on the trials related to the companys solid tumor treatment candidates will likely result in stock price growth. You can test the chance of recovery over different time intervals of a quarter, month, or even just one day! A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares. Fate Therapeutics became the first entity to dose a patient with an engineered stem cell-derived cellular medicine in October, began enrolling a higher-dose cohort for a separate drug. Janssen will also cover the funding costs of the R&D of the collaboration candidates. General & Administrative expenses jumped to $12.5 million from $7.7 million in the year-ago. The stock was sold at an average price of $5.24, for a total transaction of $38,414.44. The 16% rise for FATE stock compares with 4% gains seen in the broader S&P 500 index. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. FT819. Opinions expressed by Forbes Contributors are their own. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. The Axsome Therapeutics stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. It is a leading allogeneic (off-the-shelf) NK cell therapy developer which had just 1 IND, 87 employees, and $78mn in cash in 2018. Fate Therapeutics has received a consensus rating of Hold. While we believe that FATE stock is richly valued, the market potential is huge, especially in multi-billion dollar - oncology treatments. Is the average return for Fate Therapeutics stock higher over the subsequent month after Case 1 or Case 2? Notably, though, the stock is likely to beat S&P500 returns by 4% over the next month (twenty-one trading days). What is Fate Therapeutics' stock price today? publish chart | save to portfolio | create alert | compare perf. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. Several other hedge funds have also made changes to their positions in FATE. With the shares down 60% following Fate's announced pipeline prioritization and Janssen termination, the "damage has largely been done and there is an opportunity for value-based, longer-term investors to step in," Nochomovitz tells investors in a research note. On average, they anticipate the company's stock price to reach $24.69 in the next year. The biotech shared an interim peek of data. The stock price of Fate Therapeutics (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a 9% rise. The shares were sold at an average price of $5.24, for a total value of $240,552.68. Most of the 18x rise of the last 3 years can be attributed to expansion of its P/S multiple, as the company does not have any marketable product yet. This suggests a possible upside of 304.1% from the stock's current price. Fate is all of that. When that time comes, Janssen will have the right to exercise its option for an exclusive license for the development and commercialization of collaboration candidates targeting the tumor-associated antigens. The company said late Thursday it is working on a treatment for a blood . [] Fate Therapeutics is registered under the ticker NASDAQ:FATE . The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Subscribe to BioPharma Dive for top news, trends & analysis, The free newsletter covering the top industry headlines, By Christopher Newman and Jonathan Gardner , A preclinical trial by the U.S. National Institutes of Health validates the efficacy of Uric A, EUCOPE adds nine new innovative members to its network, From EUCOPE - European Confederation of Pharmaceutical Entrepreneurs, Ymmunobio Welcomes Dr. Kanda and Dr. Khairnar to Advisory Board, Vial Announces the Addition of Dr. Rajat N Agrawal to their Ophthalmology CRO Scientific Advis, By signing up to receive our newsletter, you agree to our, disrupting study enrollment and treatment, Bayer backs cell therapy startup with $215M in funding, Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work, 5 questions facing the pharma industry in 2023, FDA clears Intellia to start US tests of in vivo gene editing drug, Novartis takes step toward expanding supply of in-demand cancer drug, Bristol Myers, J&J plan tests of new blood thinner in nearly 50,000 patients, Exelixis reports trial failure for cancer drug combination, How to Implement a Healthy Content Moderation Strategy, How To Build Affordability Programs With Real-time Data, FDA has new power to hold drugmakers accountable. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. Fates revenue did grow a solid 160% from $4.1 million in 2017 to $10.7 million in 2019. Is the average return for Fate Therapeutics stock higher over the subsequent month after Case 1 or Case 2? Guggenheim cut shares of Fate Therapeutics from a buy rating to a neutral rating in a research note on Tuesday, January 3rd. See what's happening in the market right now with MarketBeat's real-time news feed. Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. [Updated: 3/31/2021] Can FATE Stock Rebound? Moderna leans into oncology with CytomX deal worth up to $1.2B Fate ends potential $3B Janssen partnership. Purchases New Holdings in Ball Co. (NYSE:BALL), Blueshift Asset Management LLC Sells 21,016 Shares of Dell Technologies Inc. (NYSE:DELL), Cary Street Partners Investment Advisory LLC Has $126,000 Stock Holdings in Yum China Holdings, Inc. (NYSE:YUMC). The stock has a market capitalization of $599.76 million, a price-to-earnings ratio of -2.10 and a beta of 1.53.. "From speaking to management, we think this is exactly the type of deal [Fate] was looking for," wrote Cantor Fitzgerald analyst Alethia Young, referring to a back-loaded agreement that gives the company the chance to keep some rights to the programs in the alliance. Private Advisor Group LLC now owns 9,481 shares of the biopharmaceutical companys stock valued at $367,000 after buying an additional 1,938 shares during the period. BMO Capital Markets cut shares of Fate Therapeutics from an outperform rating to a market perform rating and lowered their target price for the stock from $20.00 to $7.00 in a research note on Friday, January 6th. Once Janssen takes over the program, Fate will then be eligible to receive payments of up to $1.8 billion upon the achievement of development and regulatory milestones and up to $1.2 billion upon the achievement of commercial milestones.